Metabolomic Study in Huntington's Disease (METABO-HD)

NCT ID: NCT03296176

Last Updated: 2017-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-09

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this project is to study Huntington's disease by metabolomic approach.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Huntington Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

presymptomatic

Group Type EXPERIMENTAL

blood sample

Intervention Type BIOLOGICAL

blood sample for metabolome analyse

symptomatic

Group Type EXPERIMENTAL

blood sample

Intervention Type BIOLOGICAL

blood sample for metabolome analyse

controls

Group Type OTHER

blood sample

Intervention Type BIOLOGICAL

blood sample for metabolome analyse

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sample

blood sample for metabolome analyse

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For all groups:

* age between 20 and 70 years
* signature of the informed consent
* covered by social security

For presymptomatic group:

* positive genetic test with CAG repeat length ≥ 37 in HTT gene
* Unified Huntington Disease Rating Scale ≤ 5

For symptomatic group:

* positive genetic test with CAG repeat length ≥ 37 in HTT gene
* The Unified Huntington's Disease Rating Scale motor score ≥ 6
* The Total Functional Capacity score ≥ 11

Exclusion Criteria

* participation in another therapeutic trial (3 months exclusion period)
* pregnancy and breastfeeding
* persons deprived of their liberty by judicial or administrative decision
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Angers

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christophe Verny, PU-PH

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Angers

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Angers

Angers, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Christophe Verny, PU-PH

Role: CONTACT

Phone: 0241355615

Email: [email protected]

Dominique Bonneau, PU-PH

Role: CONTACT

Phone: 0241355615

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

VERNY

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

49RC17_0086

Identifier Type: -

Identifier Source: org_study_id